Advertisement
UK markets close in 1 hour 43 minutes

  • FTSE 100

    8,063.99
    +19.18 (+0.24%)
     

  • FTSE 250

    19,753.36
    -46.36 (-0.23%)
     

  • AIM

    755.44
    +0.57 (+0.08%)
     

  • GBP/EUR

    1.1642
    +0.0014 (+0.12%)
     

  • GBP/USD

    1.2450
    -0.0002 (-0.02%)
     

  • Bitcoin GBP

    53,129.17
    -232.19 (-0.44%)
     

  • CMC Crypto 200

    1,426.16
    +2.06 (+0.14%)
     

  • S&P 500

    5,084.02
    +13.47 (+0.27%)
     

  • DOW

    38,444.96
    -58.73 (-0.15%)
     

  • CRUDE OIL

    82.93
    -0.43 (-0.52%)
     

  • GOLD FUTURES

    2,337.60
    -4.50 (-0.19%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,122.15
    -15.50 (-0.09%)
     

  • CAC 40

    8,119.78
    +14.00 (+0.17%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

EU regulators warn against combining hep C drugs with amiodarone

Reuters - UK Focus

April 24 (Reuters) - European health regulators warned on Friday against using Gilead Sciences Inc (NasdaqGS: GILD - news) 's and Bristol-Myers Squibb Co's hepatitis C medicines along with amiodarone, a drug used to regulate the heartbeat of people with heart rhythm disorders.

The European Medicines Agency said there is a risk of severe bradycardia, or heart block, when Gilead's drug Harvoni or a combination of Gilead's Sovaldi and Bristol-Myers' Daklinza are used in patients who are also taking amiodarone. (http://bit.ly/1HvQg8n)

The agency's committee for medicinal products for human use recommended that amiodarone only be used in patients taking these hepatitis C medicines if other anti-arrhythmics cannot be administered. (Reporting by Roshni Menon in Bengaluru; Editing by Simon Jennings)